{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:55:23Z","timestamp":1767995723293,"version":"3.49.0"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,11,6]],"date-time":"2006-11-06T00:00:00Z","timestamp":1162771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Practice"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:p><jats:bold>Abstract:\u2003<\/jats:bold> This study evaluated the clinical effects and pattern of use of AVINZA<jats:sup>(r)<\/jats:sup>, morphine sulfate extended\u2010release tablets, under real\u2010world treatment conditions. Opioid\u2010naive subjects or subjects who have failed other opioids were eligible if they had chronic moderate\u2010to\u2010severe noncancer pain with an average pain score \u22654 (0\u201310 scale) in the preceding month. Subjects answered in\u2010depth monthly questionnaires in\u2003three\u2003months. For the 491 evaluable subjects enrolled, the median AVINZA dose was 30\u2003mg at baseline, titrated to 60\u2003mg by month 1, and remained at 60\u2003mg through month 3. Adherence was high, with almost 90% of the subjects reporting never having forgotten to take AVINZA. Mean daily pain scores (scale 0\u201310) significantly improved from 7.83 at enrollment to 5.77 at month 1 (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01) and then remained at this level through month 3. Significant improvements were seen in all sleep measures, and the mean Composite Sleep Score, a global measure of sleep quality (scale 0\u201310), significantly improved from 5.73 at baseline to 4.96 at month 3 (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.01). Physical functioning was improved for activities requiring a moderate effort (<jats:italic>P<\/jats:italic>\u2003=\u20030.053), such as climbing one flight of stairs (<jats:italic>P<\/jats:italic>\u2003=\u20030.008). Two hospitalizations for nausea and vomiting were the only reported drug\u2010related serious adverse events. This study showed that once\u2010daily AVINZA significantly reduced pain scores, and resulted in improved sleep and physical functioning in patients with chronic moderate\u2010to\u2010severe pain. These results were achieved with a stable daily morphine dose over the three\u2010month study period.<\/jats:p>","DOI":"10.1111\/j.1533-2500.2006.00094.x","type":"journal-article","created":{"date-parts":[[2006,11,6]],"date-time":"2006-11-06T10:49:50Z","timestamp":1162810190000},"page":"254-264","source":"Crossref","is-referenced-by-count":20,"title":["A Study of AVINZA<sup>\u00ae<\/sup> (Morphine Sulfate Extended\u2010Release Capsules) for Chronic Moderate\u2010to\u2010Severe Noncancer Pain Conducted Under Real\u2010World Treatment Conditions\u2014The ACCPT Study"],"prefix":"10.1111","volume":"6","author":[{"given":"Edgar H.","family":"Adams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Chwiecko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Ace\u2010Wagoner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Mangefrida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Duerden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George C.","family":"Perdikis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank A.","family":"Kunkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Ghalie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,11,6]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain.","author":"American Pain Society.","year":"2003"},{"key":"e_1_2_6_3_2","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research Anesthetic and Life Support Drugs Advisory Committee.Transcript of meeting of September 10 2003. Available at:http:\/\/www.fda.goc\/ohrms\/dockets\/ac\/03\/transcripts\/3978T2."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.23.4275"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.12968\/ijpn.2003.9.2.56"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125002478"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1200\/JCO.1998.16.10.3222","article-title":"Randomized, double\u2010blind, cross\u2010over trial comparing safety an efficacy of oral controlled\u2010release oxycodone with controlled\u2010release morphine in patients with cancer pain","volume":"10","author":"Bruera E","year":"1998","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-199909000-00004"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.6.853"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-8180(02)00350-1"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2299::AID-CNCR1>3.0.CO;2-O"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(03)00160-X"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3230"},{"key":"e_1_2_6_14_2","first-page":"862","article-title":"Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteropidal anti\u2010inflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial","volume":"26","author":"Caldwell JR","year":"1999","journal-title":"J Rheumatol."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(02)00328-7"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00382-2"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1191\/1078155201jp075oa"},{"key":"e_1_2_6_18_2","unstructured":"GastonguayMR JacksonK RauckR et\u2003al.Pharmacokinetic\u2010pharmacodynamic relationship of morphine and metabolites after oral administration of Morphelan\u2122 or MS Contin\u00aein patients with chronic moderate to severe pain of non\u2010malignant origin. Proc American Pain Society 20th annual meeting. 2002 (\u266f781)."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940915)74:6<1808::AID-CNCR2820740625>3.0.CO;2-Y"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2004.04.015"},{"key":"e_1_2_6_21_2","unstructured":"CataldoS RichardsPT LiaoE et\u2003al.Controlled\u2010release (CR)\u2010oxycodone (OxyContin tablets) improves pain and function in patients with osteoarthritis pain of the hip or knee as compared to usual care (oxycodone\/acetaminophen [Percocet]). Program and abstracts of the American Academy of Pain Medicine.2005;Abstract 118."},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","unstructured":"WhiteRE HarrisDJ AhdiehH MaT NagleB.Improved quality of life during long\u2010term treatment of moderate to severe pain with oxymorphone ER. APS 24th Annual Scientific Meeting 2005.","DOI":"10.1016\/j.jpain.2005.01.177"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2005.01.172"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2005.01.171"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200105000-00006"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00383-4"},{"key":"e_1_2_6_27_2","first-page":"167","article-title":"Randomized, multi\u2010center study of oral once\u2010a\u2010day AVINZA\u00ae (morphine sulfacte extended\u2010release capsules) vs. twice\u2010a\u2010day OxyContin\u00ae (oxycodone hydrochloride controlled\u2010release) for the treatment of chronic moderate to severe low back pain","volume":"2","author":"Rauck R","year":"2006","journal-title":"J Opioid Manage."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2005.01.175"},{"key":"e_1_2_6_29_2","unstructured":"AdamsEH Ace\u2010WagonerY MangefridaB DuerdenME WittMA.Interim analysis of pattern of analgesic use in chronic non\u2010cancer pain patients treated with AVINZA an extended\u2010release morphine formulation. Poster Session at the 67th Annual Meeting of the College on Problems of Drug Dependence. June 18\u201323 2005 Orlando FL Abstract 6."},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/tc.2004.008367"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2005.10.006"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(83)90143-4"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199303000-00006"},{"key":"e_1_2_6_34_2","volume-title":"SF\u201036 Physical and Mental Health Summary Scales: A User\u2019s Manual.","author":"Ware JE","year":"1994"},{"key":"e_1_2_6_35_2","volume-title":"SF\u201036 Health Survey. Manual and Interpretation Guide.","author":"Ware JE","year":"1993"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-3-3"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.09.010"},{"key":"e_1_2_6_38_2","unstructured":"AdamsEH ShaikhS HaddoxJD SchnollSH.Self reported efficacy and compliance associated with modified\u2010release opioids. Oral presentation at the 66th Annual Meeting of the College on Problems of Drug Dependence June 12\u201317 2004 San Juan PR."}],"container-title":["Pain Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1533-2500.2006.00094.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1533-2500.2006.00094.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T22:13:03Z","timestamp":1697148783000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1533-2500.2006.00094.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,6]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1111\/j.1533-2500.2006.00094.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1533-2500.2006.00094.x","archive":["Portico"],"relation":{},"ISSN":["1530-7085","1533-2500"],"issn-type":[{"value":"1530-7085","type":"print"},{"value":"1533-2500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,6]]}}}